Aleafia Health Announces Fourth Quarter and Annual Financial Results
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”)…
News
Single Use Support Further Expands Into US Market
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical…
Single Use Support Further Expands Into US Market
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical…
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental health…